{"id":"W3090684381","doi":"10.1007/s40265-020-01411-y","title":"Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Pertuzumab; Lapatinib; Medicine; Biosimilar; Neratinib; Trastuzumab emtansine; Metastatic breast cancer; Breast cancer; Oncology; Targeted therapy; Internal medicine; Cancer; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000544019,0.0002905587,0.001320798,0.0001774407,0.00004961928,0.00001632128,0.0001146554,0.0001276645,0.00007296966],"category_scores_gemma":[0.00009844833,0.000165892,0.0001199179,0.0005147506,0.0001330724,0.00002548564,0.0000669347,0.0004371032,0.00001524549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00288873,"about_ca_system_score_gemma":0.001626804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000936904,"about_ca_topic_score_gemma":0.00002577243,"domain_scores_codex":[0.9981926,0.0002170671,0.0005370312,0.000431038,0.000355448,0.0002668182],"domain_scores_gemma":[0.9992365,0.0001709797,0.0002054391,0.0002317599,0.00006095774,0.00009431807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001106871,0.00002892561,0.0002682915,0.007225155,0.000207164,0.00003252092,0.001307057,0.000005268437,0.000006619131,0.00001622704,0.001739215,0.9890529],"study_design_scores_gemma":[0.001230725,0.00007858114,0.00006563345,0.01049138,0.0002603524,0.00005663903,0.0002020423,0.00003943335,0.00004079878,0.000004105729,0.9873838,0.0001465067],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003361546,0.9895042,3.477048e-7,0.008130469,0.0001755221,0.001462778,0.00007530428,0.00002041714,0.0002948089],"genre_scores_gemma":[0.0005944364,0.9981077,0.00009120777,0.0001424519,0.0005398564,0.0002778914,0.00007455746,0.00004771688,0.0001241869],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9889064,"threshold_uncertainty_score":0.7553927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05352402178422109,"score_gpt":0.3772090738336325,"score_spread":0.3236850520494114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}